An innovative biotech with over 100 % growth both in 2011 and 2012 - BLFS
Zacks small-cap research puts an estimate of $ 0.5 - 0.7 of the company from the current - $ 0.25. The biopreservation media products market is expected to reach 10 B in 2012 from the current 1.4 B largely driven by the regenerative medicine market. BioLife expects to benefit from the emerging field of regenerative medicine and is positioning their HypoThermosol and CryoStor products as a better
alternative to other branded biopreservation media and home-brews, the latter which are estimated to hold as
much as 80% of the regenerative medicine market.